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Abstract: This review summarises the current knowledge of Gomesin (Gm), an 18-residue long,
cationic anti-microbial peptide originally isolated from the haemocytes of the Brazilian tarantula
Acanthoscurria gomesiana. The peptide shows potent cytotoxic activity against clinically relevant
microbes including Gram-positive and Gram-negative bacteria, fungi, and parasites. In addition,
Gm shows in-vitro and in-vivo anti-cancer activities against several human and murine cancers.
The peptide exerts its cytotoxic activity by permeabilising cell membranes, but the underlying
molecular mechanism of action is still unclear. Due to its potential as a therapeutic agent, the structure
and membrane-binding properties, as well as the leakage and cytotoxic activities of Gm have been
studied using a range of techniques. This review provides a summary of these studies, with a
particular focus on biophysical characterisation studies of peptide variants that have attempted to
establish a structure-activity relationship. Future studies are still needed to rationalise the binding
affinity and cell-type-specific selectivity of Gm and its variants, while more pre-clinical studies are
required to develop Gm into a therapeutically useful peptide.
Keywords: toxins; peptides; spider peptides; peptide-membrane interactions; anti-microbial peptides;
anti-cancer peptides; structure-activity relationship; rational drug design
1. Introduction
Gomesin (Gm) is a cationic anti-microbial peptide (AMP) that was originally isolated from the
haemocytes of the unchallenged Brazilian tarantula Acanthoscurria gomesiana [1]. The peptide is part
of the innate immune system of the spider and is released during microbial infection [2]. Like many
other AMPs, Gm shows cytotoxic activity against a wide range of pathogens, including clinically-relevant
Gram-positive and Gram-negative bacteria, fungi and yeast, as well as demonstrating anti-malarial [3,4],
anti-cryptococcal [5], and anti-Leishmania activity [1,3,6–11]. Gm also has in-vivo anti-cancer activity
in a mouse model of melanoma [12], and in-vitro activity against a number of other human
cancers [3,9,12–17]. In addition, Gm shows cytotoxic and anti-proliferative activity against devil
facial tumour disease [18], a “parasitic” form of cancer that threatens the extinction of the Tasmanian
devil (Sarcophilus harrisii), a unique Australian animal. A number of studies have successfully used
different types of chemical modifications, such as cyclisation and/or amino acid substitution, to
increase the anti-microbial or anti-cancer properties of Gm [3,8,9,18]. This wide range of cytotoxic
activity, combined with its high serum stability [3,6,8,9] and moderate levels of haemolysis [1,6–9],
make Gm of interest for the development of therapeutics to treat microbial infections and cancer.
Most AMPs and anti-cancer peptides (ACPs), including Gm, exert their cytotoxic activity
via membrane permeabilisation. A number of mechanisms have been proposed to explain the
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activity of AMPs/ACPs, which include, but are not limited to, the formation of pores, a ‘carpet’
(detergent-like) mechanism, and a ‘sinking raft’ model. Despite extensive research on a large number
of AMPs/ACPs, the molecular details of their mechanism of action remain poorly understood [19–24].
Some modifications that alter the physico-chemical properties of Gm result in changes to its activity yet,
other, similar modifications, have little to no effect. This clearly highlights our limited understanding
of the molecular mechanism of action of Gm (and of AMPs/ACPs in general).
The ability of Gm to permeabilise cell membranes has been established both in leakage
experiments using lipid vesicles [9,25–28] and in whole-cell experiments with bacterial [9] and cancer
cells [9,12]. Furthermore, it has been demonstrated that Gm shows a preference for membranes that
contain negatively charged lipids [3,9,26,27]. This is consistent with the view that the selectivity of
AMPs/ACPs for bacterial and cancer cells is mainly governed by electrostatic interactions between
the cationic peptides at the negatively charged lipids that are found at increased concentrations in
bacterial and cancer cells compared to healthy human cells [19,21,29–31].
A range of techniques has been used to elucidate the structure and molecular mechanism of action
of Gm. The structure of Gm in aqueous and cell membrane (or membrane-mimicking) environments has
been studied using nuclear magnetic resonance (NMR) and circular dichroism (CD) spectroscopy [7,32].
The membrane-binding properties and peptide-lipid interactions have been investigated using surface
plasmon resonance (SPR) [3,9], electron paramagnetic (EPR) spectroscopy, and isothermal calorimetry
(ITC) [25,26,28]. Other studies have focused on the intra-cellular and/or ‘downstream’ effects of
Gm [12,13,16–18,33]. In an effort to establish a structure-activity relationship, many of these studies
have not only used native (wild-type) Gm, but also a large number of Gm variants with altered
structural and/or physico-chemical properties. In fact, since the discovery of Gm, more than 40 variants
have been designed and tested. This review aims to summarise the current knowledge of Gm, with a
particular focus on its biophysical characterisation and that of its variants. The remainder of this review
is organised as follows: Section 2 summarises the in-vitro activity of Gm against the most commonly
tested microbes and cancer cell lines, the few reported in-vivo activity studies, as well as the haemolytic
activity of the peptide. Sections 3 and 4 review the studies primarily focused on the characterisation of
the structure of Gm and the relationship to its serum stability. This is followed by an overview of the
membrane-binding properties (Section 5) and the leakage activity and permeabilisation properties
(Section 6) of Gm. Section 7 is focused on the insights gained from experiments with Gm variants to
understand the role of peptide hydrophobicity and charge in cytotoxicity. Finally, Section 8 describes
the intra-cellular actions of Gm. The review concludes with a summary of our current knowledge
of Gm.
2. Cytotoxic and Haemolytic Activity of Gomesin
2.1. Anti-Microbial Activity
The original study reporting the isolation, synthesis, and biochemical characterisation of
Gm included testing the cell viability on more than 40 microorganisms, including Gram-positive
and Gram-negative bacteria, filamentous fungi and yeasts, and the eukaryotic parasite Leishmania
amazonensis [1]. Since then, the anti-microbial activity of Gm has been confirmed by a number of
independent studies [3,7–9,11,34]. Table 1 summarises the minimum inhibitory concentrations (MIC)
for the most commonly-tested microorganisms reported in these studies. The most sensitive bacterial
strains are from Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, followed by Klebsiella
pneumoniae. Gm is also very effective against clinically-relevant yeast such as Candida albicans and
Cryptococcus neoformans.
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Table 1. Anti-microbial activity of Gm for the most commonly tested microorganisms. MIC values
from different studies are combined unless they are significantly different from each other.
Microorganism MIC (µM) Reference
Escherichia coli
E. coli SBS 363 0.32–1.6 [8,11]
E. coli 1106 0.8–1.6 [1]
E. coli ATCC 25922b 4 [9]
E. coli DH5a 3.4 [3]
Pseudomonas aeruginosa
P. aeruginosa ATCC 27853b 8 [9]
P. aeruginosa * 1.6–3.15 [1]
Staphylococcus aureus
S. aureus ATCC 25923b 32 [9]
S. aureus * 1.6–3.15 [1]
Klebsiella pneumoniae
K. pneumoniae ATCC 700603b 32 [9]
K. pneumoniae * 3.15–6.25 [1]
Candida albicans
C. albicans MDM8 0.15–1.28 [8,11]
C. albicans ATCC 90028(d) 8–16 [9,34]
C. albicans 78 5.5 [34]
C. albicans * 0.15–0.30 [1]
Cryptococcus neoformans
C. neoformans ATCC 208821 0.5–1.0 [9]
C. neoformans * [1]
* Strain number not reported in the referenced study.
To the best of our knowledge, only two in-vivo studies of the anti-microbial activity of Gm
have been published. Rossi et al. investigated the efficacy of Gm against disseminated and vaginal
candidiasis in mice infected with the clinical strain of C. albicans (isolate 78) [34]. In both types
of infections, Gm effectively reduced fungal burden compared to the control group, and did so at
lower concentrations than fluoconazole (a commonly used anti-fungal agent to treat yeast infections
in humans and animals). Gm also increased the concentration of three cytokines (IL-6, TNFα and
IFNγ), indicating that it also possesses immunomodulatory activity. A synergistic effect of Gm
and fluoconazole was observed in-vitro for two isolates of C. albicans (isolate 78 and ATCC90028),
as assessed by reduced MIC values for the two compounds compared to single compound MIC.
However, in-vivo, this synergistic effect was only observed in immunocompromised mice. Moreira et al.
investigated the use of Gm as an anti-plasmodium agent against the asexual, sexual, and pre-sporogonic
forms of Plasmodium falciparum and Plasmodium berghei [4]. Gm impaired the development of both
species without any adverse effect on the survival, fecundity, and fertility of the infected mosquitoes.
2.2. Anti-Cancer Activity
The in-vitro anti-cancer activity of Gm has been demonstrated in a number of studies using a range
of murine and human cancer cell lines [3,9,12–16], as well as cells from devil facial tumour disease
(DFTD) [18]. Table 2 summarises the anti-cancer activity of Gm on the most commonly tested cell lines.
For most tested cell lines, the values from the different studies show acceptable agreement, with the
exception of HeLa cells, that show IC50/CC50 values ranging from 8.0 µM to 72.7 µM. A comparison
of the experimental protocols did not show any apparent differences that would explain the variations
in IC50/CC50 values, and no explanation for the discrepancies was provided by the authors. From
the data in Table 2, it is evident that Gm is most effective against several forms of melanoma and
leukaemia, but less so against cervical cancer cells. While it has been shown that the increased levels
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of phosphatidylserine (PS) in cancer cells are an important contribution to the selective cytotoxic
activity of AMPs/ACPs towards cancer cells [19,30,35–38], this can only partially explain why many
AMPs/ACPs, including Gm, show marked differences in activity between different types of cancer
cells [19]. The cell-type specific activity of Gm is likely dependent on additional factors such as
differences in membrane composition other than PS (e.g., gangliosides, heparan sulfate, levels of
cholesterol) [19,38,39], and/or intra-cellular effects (see also Section 8).
Table 2. Anti-cancer activity of Gm against the most commonly tested cell lines, reported as IC50, EC50
and/or CC50 ± standard deviations. Numbers is brackets indicate a 95% confidence interval.
Cell Line IC50 (µM) EC50 (µM) CC50 (µM) Reference
Skin cancer
B16 F10 (murine) 7 [13]
3.58 (2.76–4.41) [12]
MM96L (human) 5.5 ± 1.1 3.7 ± 0.2 [3,9]
SKMel 19 (human) 2.35 (1.69–3.00) [12]
A2058 (human) 1.36 (0.29–3.02) [12]
Breast cancer
SKBr3 (human) 2.87 (1.30–4.45) [12]
19.8 ± 1.2 [15]
Cervical cancer
HeLa (human) 72.7 ± 2.5 [3]
25.6 ± 1.3 [15]
8.13 (6.00–10.25) [12]
54.1 ± 5.0 [9]
Leukaemia
(human)
K562 6.2 ± 1.3 3.8 ± 0.3 [9,14]
Kasumi 10.6 ± 0.2 [14]
ARH77 6.7 ± 0.8 [14]
CCRF-CEM 13.1 ± 1.7 [14]
Devil facial
tumour disease
DFTD1,2,4 20.4, 12.29,20.41 [18]
To the best of our knowledge, there has only been one in-vivo study on the anti-cancer activity
of Gm, reported by Rodrigues et al. [12]. This study investigated the efficacy of Gm in a topical
treatment of subcutaneous murine melanoma. A Gm-containing cream was applied to animals with
established tumours. After 4 weeks, the treated animals showed a significant delay in tumour growth
and increased survival times compared to control animals. Using a series of in-vitro experiments with
the same B16 F10 melanoma cells, the authors further demonstrated that the anti-tumour activity was
due to a direct effect on cancer cells.
2.3. Haemolytic Activity
Since the main mechanism of cytotoxic activity of Gm is based on the permeabilisation of
cell membranes, it is not surprising that Gm shows haemolytic activity (it causes lysis of human
erythrocytes). For any AMP/ACP to be used as a therapeutic agent, its haemolytic activity needs to
be significantly lower than its cytotoxic activity on the target cell. This means that the concentration
required to cause a specific level of haemolysis (e.g., HD10 to obtain 10% of haemolysis) should be
higher than the MIC or IC50/EC50 for the bacterial or cancer cell of interest. Several studies have
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assessed the haemolytic activity of Gm by determining the percentage of haemolysis as a function of
peptide concentration [1,6–10]. Machado et al. [10] reported a value of 0.39 µM for the HD10 of Gm.
Although none of the other studies determined the value of HD10, in most cases it can be estimated
from the data reported: the HD10 of Gm ranges from 0.39 µM to approximately 1.0 µM [1,6–8].
Furthermore, even concentrations as high as 100 µM did not induce haemolysis to an extent higher
than approximately 40–45%. Modifications of the peptide that significantly reduce haemolysis also
reduce its antimicrobial and anti-cancer activity (and most of the time, these modifications also reduce
serum stability, see Section 4). A more successful approach is to find modifications that increase
the activity against target cells (i.e., reduced MIC or IC50/E50), but that do not alter the haemolytic
activity [9] (see Section 7). Due to our limited understanding of the molecular mechanism of Gm
and the role of specific lipids in its selectivity towards different cell types, finding such mutations is,
however, not straightforward.
3. Structure
Gm is an 18-residue peptide with the sequence ZCRRLCYKQRCVTYCRGR-NH2, where Z is
a pyroglutamic acid (pE) and R-NH2 is an amidated R [1] (Figure 1A). The solution structure of
Gm (PDB code 1KFP) was solved at 5 ◦C in 90% H2O/10% D2O at pH 3 using proton 2D NMR
by Mandard et al. [32]. The structure showed that the global fold of Gm consists of two-stranded
anti-parallel β-strands that are connected by a 4-residue non-canonical β-turn (Y7-K8-Q9-R10), referred
to as a β-hairpin-like structure. The overlay of the 20 conformations shows the presence of rigid
and well-defined β-strands and a flexible C-terminus (Figure 1B). The β-strands are connected
by two inter-strand disulfide bridges (Figure 1B,C), and are further stabilised by six inter-strand
backbone-backbone hydrogen bonds. Both disulfide bridges adopt right-handed conformations with
torsion angles close to the low energy conformations found in disulfide bonds that bridge anti-parallel
beta-strands [40,41]. The Cα-Cα distances for the two disulfide bridges are 0.38 ± 0.10 nm (C6-C11)
and 0.37 ± 0.10 nm (C2-C15). As in the case of the torsion angles, these are typical distances for
disulfide bridges found in anti-parallel β-strands. These distances are, however, considerably shorter
than the Cα-Cα distances for disulfide bridges that connect other secondary structure motifs or
β-sheets found in larger, more globular peptides/proteins [40]. Gm also exhibits an unusual β-turn.
The (i,i+3) hydrogen bond that is found in classical β-turns [42] is only present in 10 of the 20 structures.
Furthermore, K8 and Q9 show unusual backbone dihedral angles. As seen in the Ramachandran
plots (Figure 1E,F), both residues exhibit φ/ϕ angles that are outside of the favourable region (black),
or even the allowed regions (grey). The combination of φ/ϕ angles found in K8 and Q9 are not found
in any other type of β-turns [42]. Whether these unusual structural features are functionally relevant is
not yet known.
Gm is cationic, with an overall charge of +6 at physiological pH, resulting from the presence
of five R and one K residue (Figure 1A). The C- and N-termini are neutral due to amidation and
the pyroglutamic acid, respectively. Apart from positive charge, the amphiphilic nature of Gm is
another feature shared with most other AMPs/ACPs. As seen in Figure 1D, residues L5, Y7, V12,
and Y14 form a ‘hydrophobic face’ on one side of the peptide, while charged and polar residues in
the extremities of the peptide form opposing hydrophilic regions. As discussed in more detail in
Section 7, the hydrophobic face is essential for the membrane-binding and leakage activity of Gm.
Comparison to other peptides revealed that Gm shows structural and sequence similarities to a number
of AMPs/ACPs that adopt a β-hairpin-like fold, including protegrins from porcine leukocytes [43],
adroctonin from the scorpion Androctonus australis, and tachylepsin and polyphemusin from horseshoe
crabs [44,45]. In all of these peptides, the β-strands are connected by a 4-residue turn, and the
β-sheet is stabilised by two disulfide bridges. The peptides also share a relatively large percentage
of basic residues. In addition, these peptides show a similar distribution of their hydrophobic and
charged/polar residues. While all of these peptides were isolated from haemocytes, a Gm analogue
has recently been found in the venom of the Australian funnel-web spider Hadronyche infensa [18].
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angles in K8 and Q9 from the 20 structures of the NMR ensemble collected at 5 ◦C by Mandard et al. [32].
The first structure-activity relationship studies of Gm focused on investigating the role of the
disulfide bridges and the β-sheet fold in the anti-microbial and haemolytic activity of the peptide.
Fazio et al. prepared a linear variant of Gomesin (GmL) in which all four C residues were replaced
by S, thus removing the disulfide bridges [7,8]. In addition, a number of monocyclic and bicyclic
peptides using lactam bridges instead of disulfide bridges were tested. The authors referred to Gm
with two disulfide or lactam bridges as bicyclic, but this should not to be confused with the later
described cyclised version of Gm. The effect of these modifications on the structural fold of Gm
was studied using CD spectroscopy. GmL showed a spectrum typical for unordered (random coil)
structures. The bicyclic compounds were determined to adopt a β-hairpin-like fold, while monocyclic
compounds tend to adopt a combination of coils and helical structures. This suggests that both bridges
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are required for Gm to fold into its stable secondary structure. This was further confirmed by NMR
α-proton chemical shifts [7]. Comparison of the anti-microbial activity of GmL, mono- and bicyclic
Gm variants to native Gm showed that removing one bridge reduces activity, while removing both
bridges resulted in complete loss of activity. This indicates that the β-hairpin-like fold adopted in the
presence of both bridges is required for full anti-microbial activity [8]. It is, however, not the presence
of the disulfide bridges (i.e., the C residues) per se but rather, the stability of the fold that results from
inter-residue bridges that is required for activity, since bicyclic compounds with two lactam bridges
show anti-microbial activity comparable to native Gm [8]. Interestingly, replacing the C residues with
T residues to increase β-strand propensity, and stabilising the β-turn with a P residue at position 9,
rescued to some extent the loss of anti-microbial activity seen in the linear variants [7]. As the structure
of Gm is linked to its cytotoxic activity, it is not surprising that all GmL and monocyclic variants show
significantly reduced haemolysis [7,8].
Since Gm works by membrane permeabilisation, the effect of lipids or membrane-mimicking
environments on the conformation of Gm and its variants have been investigated. Domingues et al.
used CD spectroscopy to study the conformations of native Gm and a series of W-containing
Gm variants (Gm-W1, Gm-W7, Gm-W9) in the presence of anionic SDS micelles [6]. Tryptophan
residues were introduced to facilitate fluorescence studies to confirm that the peptide was bound
to the micelle surface. All three W-containing variants showed the same anti-microbial activity
as native Gm. Furthermore, the CD spectra showed that the variants exhibit the same spectral
profiles as Gm in aqueous solution, suggesting that the W-mutation did not alter the structure of
the peptide. The CD spectra collected in the presence of low SDS concentration (1 mM, below
the critical micelle concentration) indicate that Gm, as well as all W-containing variants, adopt
the same β-hairpin-like structure as in aqueous solution. At higher SDS concentrations (15 mM,
above the critical micelle concentration), the peptides undergo further structuring of the β-sheet
motif. In fact, experiments from a study by Fazio et al. [8] showed that in the presence of very
high SDS concentration (50 mM), even GmL, which is unstructured in aqueous solution, folds
into a β-sheet similar to that of native Gm. In a subsequent study, Domingues et al. confirmed
these findings by comparing the CD spectra of Gm and GmL collected in an aqueous solution
and in the presence of large unilamellar vesicles (LUVs) composed of the neutral lipid POPC
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) mixed with either 25 or 50 mol % of the negatively
charged lipid POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)) [26], as illustrated in
Fig 2. As in the case of SDS micelles, native Gm showed a slightly more pronounced β-sheet structure
in the presence of 50% POPG. The structure of GmL was determined to be very similar in an aqueous
solution and in the presence of POPC LUVs containing 25% POPG, with peaks characteristic of a
β-sheet structure only appearing when the amount of POPG was increased to 50% (Figure 2). These
studies indicate that interactions with negatively charged lipids or detergent molecules stabilise the
β-sheet fold of Gm to such an extent that the peptide can fold into a stable β-sheet structure, even in
the absence of disulfide bridges.
A number of studies have investigated a cyclised version of Gm (cyclic Gm, cGm), in which the
N-terminal Z (pE) residue is replaced with G and amidation at the C-terminus is removed. The resulting
G and R termini are chemically ligated (‘fused’) [3,10]. The NMR structure of cGm shows the same
overall fold observed in Gm, with the only difference being the removal of the disordered termini,
resulting in a more structured peptide [3]. In general, the stable β-sheet fold of Gm means that, apart
from alteration of the disulfide bridges, chemical modifications such as point mutations of one or more
residues do not significantly alter its structure [9].
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4. Serum Stability
Serum stability reflects the ability of a peptide to resist degradation by enzymes found in human
blood serum, and is critical for its successful use as a therapeutic agent [46]. Serum stability is usually
assessed by incubating a concentrated solution of a peptide with diluted human blood serum at
37 ◦C, and then determining the percentage of peptide remaining after one or multiple fixed-time
intervals. Using this approach, a number of studies have demonstrated the high serum stability of
Gm. After 6 h, at least 85% of the peptide remained detectable [7,8,10]. Even after 24 h, levels as
high as 75% of the intact peptide were detectable [9], while other studies reported approximately
35% [3]. As expected [47], the serum stability of Gm is directly related to the presence of disulfide
bridges [7,8,10]. Gm variants with only one disulfide bridge ([S2-15]-Gm, [S6-11]-Gm) show reduced
serum stability: only 40–50% of intact peptide was detectable after 1 h of incubation [8]. When both
disulfide bridges are removed, the peptide is almost completely degraded after 1 h [7,8]. Similar
to anti-microbial activity, serum stability is retained upon replacement of the disulfide bridges with
lactam bridges [7]. It has also been reported that cyclisation improves serum stability [48]. While
cGm shows the same levels of degradation after 6 h of incubation [3], it shows higher stability after
24 h [3,9]. Cyclic variants without the two disulfide bridges were slightly more stable than GmL,
but were still significantly more susceptible to degradation than native Gm or cGm [10]. Finally,
introducing residues that increase β-sheet propensity and/or D-amino acids increases resistance to
proteolysis [8,13], but still does not provide the same high serum stability observed with disulfide
bonds. It can be concluded that for optimal serum stability, both disulfide bridges need to be present,
while cyclisation can provide additional protection against degradation.
5. Permeabilisation of Cell Membranes and Leakage Activity
The ability of Gm to permeabilise cell membranes has been established, both in leakage
experiments using lipid vesicles [9,25–28], and in whole-cell experiments with bacterial [9],
yeast [5] and cancer cells [9,12]. In addition, experiments with melanoma cells have demonstrated
internalisation and cellular distributions of Gm [13]. Domingues et al. were among the first to study
the lytic mechanism of Gm [27]. They investigated the lytic activity of Gm and GmL using optical
microscopy and giant unilameller vesicles (GUVs) made of different molar fractions of neutral POPC
and negatively charged POPG (mimicking bacterial cell membranes), as well as GUVs composed
of POPC with 40% cholesterol (as a model of mammalian cell membranes). To qualitatively study
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the lytic mechanism of Gm, the authors used two complementary approaches. First, they used
microinjection of unlabelled Gm into POPC GUVs containing 1 mol % DiIC18, a lipophilic fluorescent
dye that accumulates in the membrane, and thus allows visualisation of the vesicle. Second, they
used microinjection of fluorescently labelled Gm (Gm-Rh) into GUVs composed of unlabelled POPC
or POPC/POPG (1:1 mol/mol). In both cases, the sudden bursting of the vesicles was preceded by
the local accumulation of peptides on the membrane surface (Figure 3A). The effects observed were
independent of the lipid composition and peptide, and the authors concluded that this accumulation of
peptides is part of the membrane-disrupting mechanism of Gm. An additional set of experiments were
aimed at quantifying lytic activity by using increasing concentrations of Gm and GmL against GUVs
with different membrane compositions. The ‘minimum bursting concentration’ (MBC, the lowest
concentration of peptide required to burst 90% of GUVs) was determined. As expected from the
low anti-microbial activity of GmL, its MBC is significantly higher compared to Gm (5.0 ± 0.5 µM
for GmL, 1.5 ± 0.5 µM for Gm). The reduced lytic activity of GmL was confirmed in a subsequent
study by the same authors by monitoring the peptide-induced leakage of the fluorescence probe CF
(5(6)-carboxyfluorescein) entrapped in LUVs composed of POPC and 25 or 50 mol % POPG [26]. Gm
induced rapid leakage of CF (within a few tens of seconds) in LUVs with 25 or 50 mol % POPG.
In contrast, GmL caused slower leakage in LUVs with 50% POPG, and only mild leakage in LUVs
with 25% POPG (Figure 3B). These experiments also indicated that Gm has a preference for negatively
charge membranes. For both Gm and GmL, leakage increased with increasing proportion of POPG.
In contrast, the MBC was determined to be about 3-fold higher for a LUV containing 40% cholesterol
compared to POPC only. This preference for LUVs containing negatively charged lipids was also
observed for cGm. Using CF leakage experiments, Henriques et al. reported a more than 40-fold
increase of leakage for LUVs composed of POPC/POPG (80:20 mol % i.e. 4:1) compared to POPC
LUVs [9]. In addition to lipid preferences, these leakage experiments demonstrated that Gm can induce
membrane permeabilisation through a lipid-dependent mechanism without the involvement of cell
surface receptors or other membrane proteins found in plasma membranes.
While leakage experiments with vesicles are useful to establish the concentration-dependence
of the mechanism of lysis, and can provide information on lipid selectivity, it is still important
to demonstrate membrane permeabilisation in actual cells. This is particularly important to
characterise the selectivity of Gm for specific cancer and/or bacterial cells, as their complex membrane
composition is hard to emulate in model cell membranes [49]. Rodrigues et al. [12] demonstrated
the concentration-dependent permeabilisation of Gm-treated murine melanoma cells (B16F10) by the
extracellular release of the cytoplasmic enzyme lactate dehydrogenase (LDH, an estimate of cytosolic
protein leakage) [12]. A concentration of at least 10 µM of Gm was needed to induce LDH release.
A LDH-release assay was also used by Soletti et al. to show the membrane permeability of Gm in
human neuroblastoma (SH-SY5Y) and rat pheochromocytoma cells (PC12) [17]. Compared to B16F10,
LDH release was induced at concentrations <1 µM in these cell lines (see Figure 3C). It should be noted,
however, that in the experiments with SH-SY5Y and PC12, LDH-release was assessed after incubation with
Gm for 24 h, while in the experiments with B16F10 LDH-release was determined after 5, 15, and 30 min.
Based on the above-described leakage and permeabilisation experiments, both the pore-forming
and carpet/detergent mechanisms have been suggested for Gm. While it has been proposed that the
concentration of peptide required to induce membrane damage by the carpet mechanism is higher
than for pore formation [50], at the concentrations used in the studies of Gm, both mechanisms are
feasible. Domingues et al. suggested that Gm acts via a carpet mechanism [26,27,50] due to the sudden
rupture of vesicles in leakage experiments, which was also observed previously for other AMPs [50].
The rupture was preceded by the accumulation of peptides on the membrane surface. On the other
hand, Rodrigues et al. suggested that the clustering of fluorescently labelled Gm (Gm-Rh) on the surface
of cancer cells is indicative of a pore-forming mechanism [12]. As both the carpet and pore mechanism
can be preceded by the accumulation or clustering of peptide, this can neither exclude nor confirm a
specific mechanism. Furthermore, it is possible that Gm-induced leakage in lipid vesicles proceeds
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via a different mechanism to that in cells [49,51]. Like with many other AMPs/ACPs, the exact lytic
mechanism of action of Gm remains unclear. Without knowledge of the structure of peptide-membrane
aggregates at the molecular level, and a more detailed understanding of the peptide-induced changes to
membrane morphology, both the carpet and pore-forming mechanisms are plausible.Molecules 2018, 22, x FOR PEER REVIEW  9 of 18 
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6. Membrane Binding and Peptide-Lipid Interactions
Leakage or permeabilisation necessitates membrane binding. Thus, a number of studies have
investigated the binding of Gm and its variants to both model and cell membranes using a range of
techniques [3,7,9,11,26,28].
Consistent with the increased leakage and permeabilisation of vesicles containing negatively
charged lipids, Gm shows increased binding affinity for negatively charged membranes. SPR
experiments have demonstrated that both Gm and cGm exhibit significantly increased binding to
membranes composed of POPC/POPG (4:1) [3] and POPC/POPS (1:1) [9] compared to neutral
membranes composed of POPC or POPC/POPE, as illustrated in Figure 4. This is related to the ability
of Gm to specifically target bacterial membrane surfaces, which are negatively charged. Henriques et al.
showed that cGm variants bind to the negatively charged liposaccharides (LPS) and lipoteichoic acid
(LTA) found on the surface of Gram-negative and Gram-positive bacteria, respectively [9]. As described
in Section 5, the addition of cholesterol to POPC vesicles resulted in a significant increase in the amount
of Gm required to induce leakage [27]. SPR measurements did not reveal any significant difference in
the binding of cGM to membranes composed of POPC/chol/SM (SM = sphingomyelin), compared
to membranes composed of POPC or POPE/POPE (Figure 4). Cholesterol is known to increase lipid
order while maintaining membrane fluidity, resulting in reduced permeability, which affects the ability
of AMPs/ACPs to disrupt the membrane [20,30,52]. It is thus possible that the peptides exhibit the
same degree of surface binding, as measured by SPR, while the addition of cholesterol affects the
ability of the peptide to insert into, and eventually disintegrate, the membrane, which is measured in
leakage experiments.
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The binding of Gm and GmL to SDS micelles was confirmed by Moraes et al. using EPR
spectroscopy. This study showed that, when bound to SDS micelles, the peptides exhibit significantly
increased rotational correlation times, indicating a slower and more anisotropic motion [11]. To study
the peptide-detergent interactions in molecular detail, Fazio et al. used NMR determinations with
two types of paramagnetic agents to induce selective broadening of the resonances of amino acids
that are either water exposed or buried at the water-detergent interface [7]. This approach was used
to investigate the interaction of a GmL variant with SDS micelles. In this GmL variant, denoted
[D-T2,6,11,15, P9]-D-Gm, the C residues were replaced with T residues, and Q9 was replaced by P
residues that promote the formation of β-strands and β-turns, respectively. This was combined with
the substitution of all other residues except for the P9 and G16, by their D-isomers. Residues L5, T6,
V12, T13, and Y14 in the β-strands showed much more peak broadening than residues at the termini,
while peaks from residues at the β-turn were not affected by interactions with SDS. This indicates
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that Gm lies with its β-strands roughly parallel to the surface of the SDS micelle. Unfortunately,
the experiments were not repeated with native Gm or GmL variants without the additional mutations,
and it is thus not known whether that binding mode is unique to this variant or also observed in
Gm variants with the β-turn-like fold. Also, in the absence of other structural data for lipid-Gm
interactions, it is not possible to know whether the peptide would adopt a similar binding mode when
bound to lipid vesicles or membranes.
Characterisation of the thermodynamics of interaction is critical to understanding the
membrane-binding mechanism of Gm. Domingues et al. [25,26] and Mattei et al. [28] reported a
series of ITC experiments examining the binding of Gm to POPC–POPG membranes with different
fractions of POPG. In all studies, the ITC data was analysed using a surface partitioning model
combined with the Gouy−Chapman theory. In contrast to the Langmuir model which assumes a
fixed binding constant, this approach allows the binding constant (KA) to vary as a function of free
peptide concentration, such that the apparent KA can change as more and more peptide molecules
bind to the surface. Secondly, the surface partitioning model also separates the binding affinity into
two terms: an electrostatic term that describes the concentration of peptide close to the membrane, and
a partition term that accounts for the adsorption/insertion of the peptide into the membrane. Table 3
summarises the thermodynamic parameters available for Gm binding to POPC–POPG membranes
derived from ITC experiments. For an equimolar ratio of POPC and POPG, the KA values obtained
from ITC data analysed using a partition model are 5.0 µM−1 and 0.01 µM−1. This is equivalent to
binding free energies (∆G) of −22.1 kJ mol−1 and −12.6 kJ mol−1, respectively. There do not appear
to be any apparent differences in the experimental protocols or conditions that would explain the
considerable differences in KA (and thus ∆G) in the two experiments, and the authors did not comment
on them. The KA obtained from analysis of ITC data using the Langmuir model was reported to be
5 µM−1, which is equivalent to −27.6 kJ mol−1. Consistent with the preference of Gm for binding to
negatively charged membranes, the KA for membranes with lower POPG content is reduced. However,
due to the different fractions of POPG used, the binding constants from the two studies cannot be
compared directly.
Table 3. Thermodynamic parameters determined by isothermal titration calorimetry (ITC)
measurements of the binding of Gomesin to membranes composed of POPC with different fractions of















POPC–POPG (1:1) [25] Langmuir 5 0.2 −27.6 −33.4 −5.8
POPC–POPG (1:1) [25] Partition 0.01 100 −12.6 −32.6 −20.0
POPC–POPG (1:1) [26] Partition 0.5 2 −22.1 −29.2 −7.1
POPC–POPG (3:1) [26] Partition 0.01 100 −12.6 −23.4 −10.8
POPC–POPG (7:3) [28] Partition 125 × 10−3 8.0 × 103 −2.0 −33.0 −31.0
ITC data was also used to obtain the enthalpic (∆H) and entropic (∆S) contributions to ∆G,
summarised in Table 3. Evaluation of these thermodynamic parameters shows that the binding of
Gm to POPC–POPG membranes is exothermic. While Mattei et al. state that ”interaction of Gm with
membranes is mainly enthalpy-driven, and the entropic contribution does not play a significant role”,
the data in Table 3 shows that, depending on the membrane composition and study, entropy can make
a substantial contribution to ∆G. In contrast to many helical AMPs, Gm adopts the same structure
in water and when bound to a membrane surface, and consequently, the ∆H and ∆S associated
with conformational changes is negligible. Thus, both the ∆H and ∆S contributions must arise
predominantly from the gain of peptide-lipid interactions and loss of peptide-water interactions,
as well as the release of water molecules from the water-lipid interface.
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7. The Role of Charge and Hydrophobicity in the Mechanism of Gomesin
A commonly used strategy to understand the mechanism of action of biologically-active peptides
is to prepare a series of peptide variants (also called mutants) with altered physico-chemical properties.
Comparing the activity of peptide variants to the native peptide can then be used to establish a
structure-activity relationship (SAR), which in turn could be used to design peptides with increased
potency and selectivity towards bacterial or cancer cells. Nevertheless, as evident from the combined
findings of a number of studies [6,9–11,18,28], establishing a SAR of Gm is not straightforward.
Most SAR studies of Gm have focused on investigating either the effects of changes in
hydrophobicity or charge on its membrane binding, lytic, and cytotoxic activities. Mattei et al.
designed a set of Gm variants with altered hydrophobicity/charge by replacing a single residue
in the hydrophobic face (L5, Y7, V12, and Y14) or the polar/hydrophilic areas of the peptide (R3, Q9,
R10) with an A residue (see also Figure 1) [28]. Replacing L5, Y7, V12, or Y14 with A reduces the
hydrophobicity of the peptide, while replacing the charged or polar R3, Q9, R10 with A increases
hydrophobicity (Table 4). The membrane binding of these variants to LUVs composed of POPC–POPG
(7:3 mol ratio) was measured using ITC, while their ability to permeabilise said LUVs was assessed
using CF leakage experiments. Comparison of native Gm and its variants revealed that the more
hydrophobic peptides generally have higher membrane binding affinities (Figure 5A and Table 4) and
higher percentage of leakage (Figure 5B). This indicates that hydrophobicity plays an important role
in the membrane-binding and lytic activity of Gm. The extent of this effect, however, depends on
the position of the residue that is mutated. For example, while replacing the hydrophobic residues
Y7, V12, or Y14 with an A residue reduced membrane binding to below the detection limit of ITC,
the variant with the same mutation on L5 still showed some degree of membrane binding (albeit
reduced, compared to native Gm). Similarly, the increase in membrane binding affinity is much larger
when replacing R3 with A compared to R10. A decrease in binding affinity and leakage for peptides
that are less hydrophobic can be rationalised by the fact that for the peptide to disrupt the membrane,
it must interact with its hydrophobic core. Peptides with a reduced hydrophobic character might lose
that ability. In contrast, the increased affinity of the R3 and R10 variants is somewhat counterintuitive.
While these variants follow the hydrophobicity trend, replacing R3 or R10 with A reduces the +6 charge
of native Gm to +5, yet these variants show increased binding to negatively charged membranes in
comparison to native Gm (see Figure 5A and Table 4).
Table 4. List of Gm variants with increased or decreased hydrophobicity, their charge and
thermodynamic parameters (KA,∆G, ∆H and ∆TS) for binding to POPC–POPG membranes obtained
from ITC. ∆∆Gw−→b is the difference in hydrophobicity between the variant and WT Gm based on
an experimentally determined residue-based hydrophobicity scale [53]. Negative values indicate a
peptide that is more hydrophobic. Table adapted from Mattei et al. [28]. The binding constant KA, and
thus ∆G and T∆S could only be obtained for variants with a ∆H < −20 kJ mol−1.









R3A 5 −2.7 −24.2 −36.8 50 11.7
R10A 5 −2.7 −40.1 −32.2 8 −8.6
Q9A 6 −1.7 −37.6 −30.9 5 −7.2
Gm (WT) 6 0.0 −33.0 −21.7 0.125 −11.6
V12A 6 0.4 −6.7 - - -
L5A 6 3.3 −26.8 −19.6 0.05 −7.5
Y7A 6 4.6 −6.7 - - -
Y14A 6 4.6 −4.2 - - -
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molar fraction of bound peptide (Xb) as a function of free peptide concentration (Ceq) obtained from ITC
experiments of Gm and its variants binding to LUVs composed of POPC–POPG 7:3 (mol ratio); (B) Top
panel: Kinetics of CF leakage from LUVs composed of POPC–POPG 7:3 (mol ratio) after addition
of Gm and its variants at a peptide-molar ratio of 0.12 at room temperature (~23 ◦C). Bottom panel:
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fro Mattei et al. [28]. Copyright 2014 American Chemical Society; (C). Binding of cyclic Gm (cGm)
and its variants to model membranes co posed of POPC and –POPG (4:1 molar ratio) from
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a ptide conce tration of 32 µM. Right panel: Dose-response binding curves from the different
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In this respect, Henriques et al. studied the membrane binding, leakage, and cytotoxic activity
of a range of cGm variants, including some that alter the charge of the peptide [9]. Compared
to the +6 charge of cGm, the variants cGm[G1K,K8R] and cGm[R4A,R18A] have a charge of
+8 and +4, respectively. Based on the ‘hydrophobicity trend’ alone, cGm[G1K,K8R] with its
reduced hydrophobicity should show decreased binding, while the increase of hydrophobicity in
cGm[R4A,R18A] should increase binding. However, SPR experiments with membranes composed of
POPC–POPG (4:1 molar ratio) reveal that both peptides have similar binding affinities (Figure 5C).
The only difference in their binding is that cGm[R4A,R18A] has a slower association rate, consistent
with its reduced charge, while cGm[G1K,K8R] has a reduced dissociation rate (Figure 5C). The leakage
activity of both of these variants is also inconsistent with the ‘hydrophobicity trend’. cGm[R4A,R18A]
showed a 4-fold reduction in its ability to induce leakage in LUVs composed of POPC–POPG (4:1 molar
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ratio), while cGm[G1K,K8R] shows a 4-fold increase in leakage. Another example is the truncated
variant cGm(2−15), where pE1 and R16-G17-R18 were removed. This peptide has a reduced charge,
and thus, increased hydrophobicity, but the variant shows reduced anti-microbial activity, implying
a reduced leakage activity [10]. Finally, for cancer cells, an increase in membrane binding and lytic
activity does not necessarily translate into increased cytotoxic activity. The Gm-R3A mutant has a
higher binding affinity and induces more leakage than Gm [28], but it shows no cytotoxic activity
against DFTD [18] or melanoma cells (Ikonomopoulou et al., unpublished).
These studies with Gm variants indicate that while hydrophobicity is important for the membrane
binding and lytic activity of the peptide, there is no general trend that is predictive. The specific activity
of a variant is more likely to result from the fine balance between the overall hydrophobicity and
charge of the peptide, as well as the spatial distribution of hydrophobic/non-polar and polar/charged
residues on the surface of the peptide, as this will dictate the extent to which the peptide can bind to and
insert into the membrane. In some cases, membrane-binding and lytic activity on model membranes
might not translate into cytotoxic activity [51]; this highlights the complexity of membrane-disrupting
mechanisms of AMP/ACPs.
8. Intra-Cellular Effects
A number of studies have shown that, in addition to causing cell death by permeabilisation, many
AMPs and ACPs also exert cytotoxicity via several intracellular mechanisms (see Gaspar et al. [19] and
references therein). In the case of Gm, it has been shown that it affects programmed cell death [13,17,18,33,54],
expression levels of cell cycle proteins [18], generation of reactive oxygen species (ROS) [17,18], and
the intracellular levels of Ca2+ [16,17,33].
Experiments using CHO cells [33], B16F10 mouse melanoma cells [12,13], and K562 cells [14] have
shown that Gm can be internalised at concentrations below the ones required for permeabilisation.
Once inside the cell, the peptide can interfere with necrotic or apoptotic pathways in a cell-type specific
manner. Experiments with K562 cells showed that cell death was primarily induced via apoptosis [16].
On the other hand, necrosis seems to be the dominant pathway in SH-SY5Y [17] and B16F10 [12] cells,
neither of which showed any signs of apoptosis. Similarly, Gm induces necrosis in DFTD4 cells [18].
It is thus likely that the detailed mechanism is cell-type specific.
In some cell types, Gm-induced cell death is associated with changes of intracellular Ca2+ levels.
For example, Paredes et al. [33] showed that in CHO cells membrane permeabilisation was preceded
by an elevation of cytosolic Ca2+ concentrations. This was accompanied by a release of Ca2+ from the
endoplasmic reticulum followed by a disturbance of the cell mitochondria and lysosomes. In another
study, the same authors also showed increases of Ca2+ levels in K562 cells after treatment with
Gm [16]. The role of Ca2+ in Gm-induced cell death was also demonstrated in SH-SY5Y and PC12
cells [17]. Ca2+ influx increase evoked by Gm was significantly reduced when pre-treating cells with
nimodipine, a blocker of L-type voltage-dependent calcium channels. Furthermore, the increase of
Ca2+ levels activated a number of signalling pathways resulting in the increase of ROS. The authors
concluded that the Gm-induced cytotoxicity of human neuroblastoma cells involves “calcium entry
through L-type voltage-dependent calcium channels”, activation of kinase signalling pathways, and
generation of ROS. Increased generation of ROS was also shown for DFTF4 cells treated with Gm
and its variants [18]. The same study also showed the presence of other hallmarks of cellular stress in
Gm-treated cells, including changes in the expression of cell cycle inhibitory proteins p53, p27, and p21,
as well as diminished mitochondrial membrane potential that correlated with a significant reduction
of the G0/G1 cell cycle phase. All of these experiments clearly show that, in addition to membrane
permeabilisation, Gm can promote cell death through a range of cell-type specific mechanisms.
9. Conclusions
Since its original discovery and isolation, a number of studies have confirmed the cytotoxic activity
of Gm against a range of clinically-relevant microbes as well as cancer cells. The therapeutic potential
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of Gm to treat candidiasis and as an anti-cancer agent to treat melanoma has been confirmed in mouse
models. The biophysical characterisation of Gm and Gm variants has shown that the β-sheet structure
is required for its anti-microbial and anti-cancer activity, as well as its serum stability. Attempts to
reduce the haemolytic activity of Gm demonstrated that this is usually accompanied by reduced
anti-microbial and anti-cancer activity. It is, however, possible to improve the activity against target
cells while not altering haemolytic activity, thus improving the overall therapeutic index of the peptide.
Studies of the membrane binding and lytic activities of Gm and Gm variants have demonstrated that
both hydrophobicity and charge are important for the cytotoxic activity of Gm. Improving cytotoxic
activity or selectivity is, however, not as simple as increasing hydrophobicity and/or charge, but
rather, more a case of finding an optimal distribution of hydrophobic/non-polar and polar/charged
residues on the surface of the peptide. Without a more detailed understanding of the peptide-lipid
interactions at the molecule level, a rational design of variants with improved cytotoxic activity or
selectivity remains a non-trivial task.
In the search for establishing a SAR and finding variants of improved cytotoxic activity, it has
also become clear that the detailed mechanism of Gm depends on a number of factors, including
peptide concentration and cell type. At low concentrations, Gm can alter programmed cell death,
expression levels of cell cycle proteins, and alter intra-cellular levels of Ca2+. The details of the
pathways and processes involved are cell type-specific. At higher concentrations, Gm causes cell death
via membrane permeabilisation. Even if the presence of negatively charged lipids such PS on cancer
cells or LPS on Gram-negative bacteria can explain the selectivity of Gm over healthy mammalian
cells, it is not clear why Gm shows marked differences in activities across different cancer cell lines
or bacterial strains. Further research is needed to establish whether these are based on differences in
membrane composition, intra-cellular effects, or both. Understanding the effect of specific lipids on
the membrane-disrupting activity and cell-type-specific selectivity of Gm (and other AMPs/ACPs)
will require the systematic study of vesicles or membranes of various lipid compositions, as well as
the use of more realistic model membranes that better mimic healthy mammalian cells and cancer or
bacterial cells. Finally, to establish the clinical use of Gm to treat microbial infections or cancer, more
pre-clinical studies using animal models are required [19,55].
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